Cancer Research

Modern oncology relies on complex 3D tissue models - such as organoids and spheroids - to accurately replicate the human tumour microenvironment. While these models provide a superior platform for drug discovery compared to traditional 2D cultures, they present significant technical challenges in terms of uniform cultivation, imaging penetration and reproducible expansion.

Cancer Research: Precision from Bench to Bedside

We support oncology research and translational medicine by providing world-leading scientific instruments, process equipment, and consumables. We help our customers enhance assay development, achieve high-throughput screening efficiency, and establish robust technical frameworks to advance therapies with confidence.

Cultivation & Model Reproducibility

Establishing consistent 3D cell models is the foundation of reliable oncology data. The scientific decisions made during early-stage culture define the accuracy, consistency, and statistical relevance of your downstream drug screening assays.

Optimised 3D Culture Expansion: Transitioning complex models to higher-throughput formats requires uniform gas exchange and minimal shear. Thomson Instrument Company Optimum Growth® flasks and high-throughput plates provide the superior aeration and growth dynamics needed to develop robust, uniform 3D spheroids and organoids while maximising incubator space.

Advanced Imaging & Phenotyping Profiling

Analysing thick, non-uniform biological structures requires advanced imaging capabilities that go far beyond standard microscopy. Capturing high-resolution data throughout the 3D volume is critical for evaluating drug efficacy.

Automated 3D Analysis: We partner with SYNENTEC to provide automated imaging systems (NYONE® and CELLAVISTA®) with high-throughput analysis tailored to the complexities of 3D cell models. These platforms feature dedicated focus algorithms to image organoids and spheroids accurately across 96- and 384-well formats.
AI-Driven Phenotyping: SYNENTEC’s YT-Software® utilises deep-learning algorithms to extract precise quantitative parameters in real time. This enables automated, label-free or fluorescent monitoring of cell viability, compound toxicity and structural volume changes following therapeutic treatment.

Advancing Precision Oncology and Drug Discovery

Moving targeted drug candidates from academic research to clinical application requires rapid, data-rich screening workflows that de-risk early-stage pipelines.

High-Speed Lead Identification: Automated image acquisition and processing enable high-throughput screening of patient-derived cell populations, allowing research teams to identify promising drug candidates faster.
Definitive Data Integrity: By combining high-density 3D culture with quantitative image analysis, oncology teams gain definitive proof of drug response and cellular mechanism, ensuring complete scientific confidence when advancing candidates toward clinical trials.

The BPES Advantage in Oncology

We understand that in cancer research, ‘accuracy is the path to a cure.’ By integrating the high-performance cultivation tools of Thomson with the industry-leading automated imaging of SYNENTEC, we provide the end-to-end precision required to advance the frontiers of oncology.